Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0GC5H
|
|||
| Former ID |
DCL000318
|
|||
| Drug Name |
Ramatroban
|
|||
| Synonyms |
116649-85-5; Baynas; BAY u3405; Bay u-3405; Bay u 3406; Bay-u-3405; Bay u 3405; BAY-u 3405; UNII-P1ALI72U6C; C21H21FN2O4S; 3-[(3R)-3-[(4-fluorophenyl)sulfonylamino]-1,2,3,4-tetrahydrocarbazol-9-yl]propanoic acid; P1ALI72U6C; 3-(4-Fluorophenylsulfonamido)-1,2,3,4-tetrahydro-9-carbazole propanoic acid; CHEMBL361812; (+)-(3R)-3-(p-Fluorobenzenesulfonamido)-1,2,3,4-tetrahydrocarbazole-9-propionic acid; NCGC00167519-01; EN-137774; DSSTox_RID_81819; Baynas (TN); Ramatroban (JAN/INN); [3H]ramatroban
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Perennial allergic rhinitis [ICD-11: CA08.03; ICD-10: J30.3] | Phase 2/3 | [1], [2] | |
| Company |
Bayer Yakuhin
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H21FN2O4S
|
|||
| Canonical SMILES |
C1CC2=C(CC1NS(=O)(=O)C3=CC=C(C=C3)F)C4=CC=CC=C4N2CCC(=O)O
|
|||
| InChI |
1S/C21H21FN2O4S/c22-14-5-8-16(9-6-14)29(27,28)23-15-7-10-20-18(13-15)17-3-1-2-4-19(17)24(20)12-11-21(25)26/h1-6,8-9,15,23H,7,10-13H2,(H,25,26)/t15-/m1/s1
|
|||
| InChIKey |
LDXDSHIEDAPSSA-OAHLLOKOSA-N
|
|||
| CAS Number |
CAS 116649-85-5
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
7848191, 7980465, 10240891, 12014153, 14806727, 14904588, 29304055, 50064212, 50112772, 53788138, 57340633, 79986756, 92719267, 93310921, 103444835, 104048051, 104419548, 118046311, 126592924, 126628292, 126650406, 126666119, 128475209, 134338974, 135079755, 135650884, 135651196, 135698277, 136910242, 137923239, 144206069, 152106038, 152164410, 152246312, 162248522, 163305476, 163392631, 170465980, 174006902, 179149649, 186021988, 187072440, 196111770, 198937833, 204379957, 208265308, 210279843, 210282166, 223554817, 223655760
|
|||
| ChEBI ID |
CHEBI:32087
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Prostaglandin D2 receptor 2 (PTGDR2) | Target Info | Antagonist | [3] |
| Thromboxane A2 receptor (TBXA2R) | Target Info | Antagonist | [4] | |
| KEGG Pathway | Calcium signaling pathway | |||
| Neuroactive ligand-receptor interaction | ||||
| Platelet activation | ||||
| Reactome | Prostanoid ligand receptors | |||
| G alpha (q) signalling events | ||||
| G alpha (12/13) signalling events | ||||
| Thromboxane signalling through TP receptor | ||||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Gastrin-CREB signalling pathway via PKC and MAPK | ||||
| Small Ligand GPCRs | ||||
| Signal amplification | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 1911). | |||
| REF 2 | ClinicalTrials.gov (NCT00311051) Ramatroban/Montelukast Versus Montelukast/Placebo on the Early Allergic Reaction in Asthma Sensitive to House Dust Mite. U.S. National Institutes of Health. | |||
| REF 3 | CRTH2-specific binding characteristics of [3H]ramatroban and its effects on PGD2-, 15-deoxy-Delta12, 14-PGJ2- and indomethacin-induced agonist resp... Eur J Pharmacol. 2005 Nov 7;524(1-3):30-7. | |||
| REF 4 | Participation in cysteinyl leukotrienes and thromboxane A2 in nasal congestion model in Brown Norway rats. Int Immunopharmacol. 2007 Nov;7(11):1483-7. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.